Skan Group Ag · SIX:SKAN
Skan — FY2024 Earnings Presentation
31 slides from Skan's earnings presentation, Mar 25, 2025
Slide 1: Presentation of the 2024 Financial Results
SKAN Group AG Presentation of the 2024 Financial Results 25 March 2025
Slide 2: Disclaimer
SKAN Disclaimer THIS PRESENTATION AND ITS CONTENTS ARE CONFIDENTIAL AND ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY JURISDICTION WHERE SUCH DISTRIBUTION IS UNLAWFUL. Th
Slide 3: Agenda
SKAN Agenda 1. Overview of Business Year Thomas Huber (CEO) 2. 3. 4. 5. 6. 25 March 2025 SKAN Group AG Presentation of the 2024 Financial Results 3
Slide 4: Highlights of the financial year 2024
SKAN Highlights of the financial year 2024 Order Intake Net Sales Strong order intake growth based on significant increase in requests in CHF million in CHF million for quotations and high success rate. 359.5 361.3 Order backlog and book-to-bill ratio at 1.0 offer planning security for +21.8%(1) +12
Slide 5: Both segments progressing well
SKAN Both segments progressing well Equipment & Solutions Good sales of large-scale filling isolators, e.g. for ADC’s (Antibody Drug Conjugates) or GLP-1 substances. Good progress with the strategic initiatives in the areas of integrated process systems and standardization. SKAN once again invested
Slide 6: Agenda
SKAN Agenda 1. 2. Strategy execution Thomas Huber (CEO) 3. 4. 5. 6. 25 March 2025 SKAN Group AG Presentation of the 2024 Financial Results 6
Slide 7: Group's growth strategy
SKAN Group’s growth strategy SKAN Objectives: Continue growth track-record Increase recurring revenue base Expand profitability 1 2 Expand addressable market 3 Increase exposure to after- 4 Accelerate digital Fortify market leadership towards integrated process market services & transformation syste
Slide 8: Strategy execution in 2024
SKAN Strategy execution in 2024 Objectives: Continue growth track-record Increase recurring revenue base Expand profitability 1 2 Expand addressable market 3 Increase exposure to after- 4 Accelerate digital Fortify market leadership towards integrated process market services & transformation systems
Slide 9: Customer proximity strengthened through accelerated decentralization
SKAN Customer proximity strengthened through accelerated decentralization Allschwil CH Gembloux BE Headquarters / production sites Production site / AT • Engineering, sales, • Aseptic Filling service, assembly, equipment (Closed R&D, laboratories Vial® Technology) • Approx. 26,682 m 2 • Approx. 3,59
Slide 10: SKAN do Brasil – opens subsidiary in São Paulo
SKAN do Brasil – SKAN SKAN opens subsidiary in São Paulo The new office was established in São Paulo on 5 February 2024. In future, direct sales, service and customer support for SKAN isolator systems in Brazil will be provided from there. The SKAN Group sees considerable potential for its high-qual
Slide 11: New drugs increase consumption of AT-Closed Vial
New drugs increase consumption of AT-Closed Vial® SKAN Eight AT filled drugs on the market: Customer Product area Phase Sales of AT-Closed Vial® and associated disposable products such as filling kits were a driver for the Services & DELYTACT®: Oncolytic virotherapy for brain Consumables business. c
Slide 12: Milestones: Pre-Approved Services commercial in H2/2026
SKAN Pre-Approved Services commercial in H2/2026 With Pre-Approved Services, SKAN will offer customers the Key data possibility to carry out their stability tests on our systems. Equipment: This will allow our customers to shorten the time-to-market At start: filling equipment with potential to expa
Slide 13: Agenda
SKAN Agenda 1. 2. 3. Financial Results 2024 Burim Maraj (CFO) 4. 5. 6. 25 March 2025 SKAN Group AG Presentation of the 2024 Financial Results 13
Slide 14: Order intake momentum continues steadily at elevated levels
SKAN Order intake momentum continues steadily at elevated levels Order intake Order intake by regions Comments (CHFm) (CHFm and ∆ in %) (1) After normalized order intake at a healthy 0.9x 1.0x level in the previous year, the order intake +17.6% increased by 21.8% driven by large +52.1% systems inclu
Slide 15: Continued net sales growth with stable order backlog
SKAN Continued net sales growth with stable order backlog Net sales Order backlog Comments (CHFm and ∆ in %) (CHFm and ∆ in %) +12.9% ~21% stronger net sales +2.0% Net sales grew by +12.9% y-o-y in 2nd half of the year 361.3 318.3 At constant exchange rates (CER), 312.1 growth reached 13.6%, below +
Slide 16: Margin improvement through product mix and effective cost management
SKAN Margin improvement through product mix and effective cost management Expenses EBITDA Comments (CHFm) (CHFm and margin in %) EBITDA increased by 13.6% to CHF 57.0m, resulting in an EBITDA margin of 15.8%, +216 +83 15.7% 15.8% ~65% stronger EBITDA supported by contributions from product in 2nd ha
Slide 17: Segment Equipment & Solutions (E&S)
SKAN Segment Equipment & Solutions (E&S) Order intake Net sales EBITDA Comments (CHFm) (CHFm and as of % of Group net sales) (CHFm and margin in %) 289.9 283.0 74.1% 75.0% 11.3% 11.2% Strong order intake driven by large systems incl. ADC’s and GLP-1 orders. The latter +19.6% +14.3% +12.9% amounted a
Slide 18: Segment Services & Consumables (S&C)
SKAN Segment Services & Consumables (S&C) Order intake Net sales EBITDA Comments (CHFm) (CHFm and as of % of Group net sales) (CHFm and margin in %) 22.3 35.4 25.9% 25.0% 28.1% 29.5% Order intake growth of +27.6% driven by AT consumables but also large spare parts orders and +27.6% +9.0% +14.4% retr
Slide 19: Cash flow and ROCE driven by increased profitability despite significant growth capex
SKAN Cash flow and ROCE driven by increased profitability despite significant growth capex Cash flow Return on capital employed (1) Comments (CHFm) (CHFm and in %) Operating cash flow rose significantly, from CHF 8.7m to CHF 46.7m primarily -31.4 21.5% (-36.9%) driven by increased profitability, red
Slide 20: Strong balance sheet & finance structure
SKAN Strong balance sheet & finance structure Balance sheet as of 31 Dec. Comments (CHFm) +3.0% +3.0% SKAN Group posts a net cash position 384.5 384.5 of CHF 43.1m as of 31st December 2024 373.4 373.4 and is thus very well positioned to finance future growth. Fixed term deposit of CHF 8.1m not Other
Slide 21: 14% higher dividend proposal vs. previous year
SKAN 14% higher dividend proposal vs. previous year Dividend per share Earnings per share Comments (CHF) (CHF) Proposed dividend of CHF 0.40/share (2023: 0.35/share) 50% from capital contribution reserves ("KER") +14.3% +47.5% 50% from retained earnings 1.73 Distribution of CHF 9.0m (PY: CHF 7.9m) 0
Slide 22: 2024 — At a glance
2024 — At a glance SKAN CHF 361.3m +13.6% 1 Consistent above-market growth net sales growth y-o-y net sales at constant exchange rates (CER) 1.0x CHF 318.3m 2 Top-line visibility supported by high order intake and order backlog book-to-bill ratio order backlog (based on order intake 2024) as of 31 D
Slide 23: Agenda
SKAN Agenda 1. 2. 3. 4. Sustainability Thomas Huber (CEO) 5. 6. 25 March 2025 SKAN Group AG Presentation of the 2024 Financial Results 23
Slide 24: Sustainability policy driven forward
SKAN Sustainability policy driven forward Strategy in place Group-wide ESG strategy has been established. Ensures that sustainability considerations are systematically integrated into business activities. Responsibilities defined Board of Directors level: Vice President Cornelia Gehrig Executive Boa
Slide 25: Sustainability highlights
SKAN Sustainability highlights Isolators enable the filling of life-saving Certified as medication: cancer drugs, cell & gene drugs, hormones, vaccines, … “great place to work” Certified (2) equal pay policy 20-30% more energy efficient isolator technology 87’799 hours of training in 2024. compared
Slide 26: Agenda
SKAN Agenda 1. 2. 3. 4. 5. Outlook Thomas Huber (CEO) 6. 25 March 2025 SKAN Group AG Presentation of the 2024 Financial Results 26
Slide 27: Market and business outlook
SKAN Market and business outlook Market development Business development SKAN Group is focused on a market that is benefiting from Due to the nature of the project business, there may be delays structural growth. Main drivers are: in the execution of orders. From today's perspective, the BoD The und
Slide 28: Guidance
SKAN Guidance Metric 2025 Targets (1) Mid-Term Outlook Group net sales growth Mid-teens Mid- to upper teens (2) Segment net sales growth E&S S&C E&S S&C Gradually increase profitability level to upper EBITDA margin 14 - 16% teens in the mid-term. Potential for further increase beyond mid-term period
Slide 29: Questions and discussions
SKAN Agenda 1. 2. 3. 4. 5. 6. Questions and discussions 25 March 2025 SKAN Group AG Presentation of the 2024 Financial Results 29
Slide 30: Together always one step ahead!
Together always one step ahead!
Slide 31: Abbreviations and Definitions
SKAN Abbreviations and Definitions Alternative Financial Performance Measures (APM) EBITDA: Operating result (EBIT) plus depreciation, amortisation. Net working capital (NWC): Total current assets (excluding cash and cash equivalents) minus trade payables, advance payments from EBITDA margin: EBITDA